Emerging SARS-CoV-2 variants raise questions about escape from previous immunity. As the population immunity to SARS-CoV-2 has become more complex due to prior infections with different variants, ...
Fig. 4: Distributions of VRC01 serum PT 80 against viruses acquired by placebo recipients, within each virus neutralization IC 80 sensitivity category. Fig. 5: PT 80 values to autologous acquired ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve at a rapid pace, generating new variants that arouse concern. Variants that were first detected in California (B.1.429 ...
The neutralizing activity of all serum samples was tested against the B.1.429 variant and a variant of concern that first emerged in South Africa (B.1.351, also called 20H/501Y.V2). We compared this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results